Roche lost Indian patent as it didn't comply local norms:Govt

Roche was granted a patent on April 6, 2007 but faced a post grant challenge

Press Trust of India New Delhi
Last Updated : Aug 05 2013 | 7:08 PM IST
Swiss pharma major Roche Holding lost an Indian patent for breast cancer drug 'Herceptin' as it did not comply with local norms after facing a post grant challenge, government said today.

Roche had filed for patent of 'Herceptin' on October 11, 2000 and was granted a patent on April 6, 2007 but faced a post grant challenge.

Following it, according to the Ministry of Commerce and Industry, the Controllers of the Patent Office gave the company opportunity under three applications filed by it "of being heard before the final disposition of these cases".

Also Read

Rubbishing reports that Indian government has revoked the company's patent, the ministry said it had lapsed due to the procedural delays on part of the Swiss company.

"Before the Controllers issued their decisions, the applicants were given due opportunity of being heard but the applicants have chosen not to attend."

"It is submitted that in the instant cases, the Patent Office has followed the due course of principle of natural justice, gave the applicant the opportunity of being heard and then only finally disposed of the matter," the ministry said in a statement.

In the instant cases, it is found that proper steps for filing request or filing divisional applications were not followed by the applicants, it added.

Comments from Roche could not be obtained as an emailed query remained unanswered.

Putting the blame squarely on the pharmaceutical major, the ministry said: "If the requests are not filed within time they are treated as withdrawn under section IIB(4) of the (Indian Patents) Act".

Elaborating how the company had failed to adhere to deadlines, the ministry said "the patent controller found that the Request for Examination had been filed on 17.03.2006, i.e., beyond the prescribed period (which was due on 16.02.2006)" as per the Indian patent norms.

It further said two separate dates were given to the company this year by the controller to hear its case but "the agent of the applicant did not appear in the hearing and even did not submit any notes of argument. Under these circumstances, the controller ordered that the application should be treated as withdrawn."
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 05 2013 | 7:02 PM IST

Next Story